Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis.

Published

Journal Article

Intestinal mucositis is one of the major troublesome side effects of anticancer chemotherapy leading to poor patient compliance. In this study we addressed the role of the novel apolipoprotein E (ApoE) COG 133 mimetic peptide in 5-fluorouracil (5-FU)-challenged Swiss mice and IEC-6 cell monolayers. Experiments were also conducted in C57BL6J ApoE knock-out mice to assess the effects of apoE peptide treatment.Experimental groups were as follows: unchallenged controls, 5-FU-challenged mice (450 mg/kg, i.p) with or without the ApoE peptide (0.3, 1, and 3 μM, given twice daily i.p. for 4 days). Mice were sacrificed 3 days after 5-FU challenge. Proximal small intestinal samples were harvested for molecular biology and histological processing. We conducted ELISA assays and RT-PCR to target IL-1β, TNF-α, IL-10, iNOS, and myeloperoxidase (MPO) to assess intestinal inflammation. Cell death and NF-κB assays were also conducted in apoE knock-out mice. In our in vitro models, IEC-6 cells were exposed to 1 mM of 5-FU in glutamine free media with or without the ApoE peptide (0.02, 0.2, 2, 5, 10, and 20 μM). We investigated IEC-6 cell proliferation and migration, 24 h after the 5-FU challenge. Additionally, apoptotic IEC-6 cells were measured by Tunel and flow cytometry. Equimolar doses of the ApoA-I (D4-F) peptide were also used in some experiments for comparative studies.Villus blunting and heavy inflammatory infiltrates were seen in the 5-FU-challenged group, findings that were partially ameliorated by the ApoE peptide. We found increased intestinal MPO and pro-inflammatory IL-1β and TNF-α levels, and TNF-α and iNOS transcripts, and reduction of IL-10 following 5-FU treatment, each of which were partially abrogated by the peptide. Improvements were also found in IEC-6 cell apoptosis and migration following ApoE and D-4F treatment.Altogether, these findings suggest that the novel ApoE COG 133 mimetic peptide can reduce 5-FU-induced intestinal changes and potentially benefit mucositis.

Full Text

Duke Authors

Cited Authors

  • Azevedo, OGR; Oliveira, RAC; Oliveira, BC; Zaja-Milatovic, S; Araújo, CV; Wong, DVT; Costa, TB; Lucena, HBM; Lima, RCP; Ribeiro, RA; Warren, CA; Lima, AÂM; Vitek, MP; Guerrant, RL; Oriá, RB

Published Date

  • July 13, 2012

Published In

Volume / Issue

  • 12 /

Start / End Page

  • 35 -

PubMed ID

  • 22524518

Pubmed Central ID

  • 22524518

Electronic International Standard Serial Number (EISSN)

  • 1471-230X

International Standard Serial Number (ISSN)

  • 1471-230X

Digital Object Identifier (DOI)

  • 10.1186/1471-230X-12-35

Language

  • eng